SEC Company Response from BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308) (ONC) — Feb 1, 2016
BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308)
Date: Feb. 1, 2016 · CIK: 0001651308 · Accession: 0001193805-16-002319
AI Filing Summary & Sentiment
File numbers found in text: 333-207459, 333-209044
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
[CITIBANK LETTERHEAD]
February 1, 2016
Via EDGAR and Telecopier
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Paul Dudek, Esq
Division of International Corporate Finance
Fax: (202) 772-9207
Re:
BeiGene, Ltd.
Registration Statement on Form F-6 (Registration No.: 333-209044)
Dear Mr. Dudek:
Citibank N.A., as depositary (the “Depositary”) and acting solely on behalf of the legal entity created by the Form of Deposit Agreement, by and among the Depositary, BeiGene, Ltd., an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (the “Company”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder representing ordinary shares, par value of US$0.0001 per share, of the Company, hereby requests that the effectiveness of Registration Statement on Form F-6 (Registration No.: 333- 209044) be accelerated to coincide with the accelerated effectiveness of the Company’s Registration Statement on Form S-1 (File No.: 333-207459).
Please call me at (212) 816-7937 if you have any questions.
Very truly yours,
CITIBANK, N.A.
By:
/s/ Leslie Deluca
Name:
Leslie Deluca
Title:
Vice President
cc: Herman H. Raspé, Esq. (Patterson Belknap Webb & Tyler LLP)